The activity of unloaded gelatin nanoparticles on murine melanoma B16-F0 growth in vivo

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1027-1031

  Farrugia, Claude A ^a   Groves, Michael J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Gelatin nanoparticles; In vivo; Melanoma; Murine

Indexed keywords

BCG VACCINE; FIBRONECTIN; GELATIN; IMMUNOSTIMULATING AGENT; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BCG VACCINE; FEMALE; FIBRONECTINS; GELATIN; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL;

EID: 0033024701     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. American Cancer Society: Skin cancer. In: Cancer facts and figures (American Cancer Society, ed). Atlanta, American Cancer Society, 1998.
2. Morton D, Foshag L, Hoon D, Nizze J, Wanek L, Chang C, Davtyan D, Gupta R, Elashoff R, and Irie R: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216: 463-482, 1992.
3. Groves M: BCG: the past, present and future of a tuberculosis vaccine. J Pharm Pharmacol 49: 7-15, 1997.
4. Nightingale S: BCG Live approved for carcinoma in situ of the urinary bladder. JAMA 264: 677, 1990.
5. Proctor J, Auclair B, and Lewis M: The effect of BCG on B-16 mouse melanoma: a comparison of routes of administration on tumour growth at different anatomical sites. Eur J Cancer 12: 203-210, 1976.
6. Morton D, Eilber F, Holmes E, Sparks F, and Ramming K: Present status of BCG immunotherapy of malignant melanoma. Cancer Immunol Immunother 1: 93-98, 1976.
7. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, Bufalino R, Cascinelli N, Cocconi G, Durand J, De Marsillac J, Ikonopisov R, Kiss B, Lejeune F, MacKie R, Madej G, Mulder H, Mechl Z, Milton G, Morabito A, Peter H, Priario J, Paul E, Rumke P, Sertoli R, and Tomin R: A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307: 913-916, 1982.
8. Skoutelis A, Melekos M, and Bassaris H: Miliary tuberculosis secondary to transurethral Bacillus Calmette-Guérin administration for superficial transitional cell carcinoma of the bladder. J Natl Cancer Inst 82: 1219-1220, 1990.
9. Klegerman M, Ujjainwala L, and Zeunert P: High-dose inhibition and low-dose enhancement of murine sarcoma growth exhibited by BCG vaccine. Cancer Lett 56: 137-145, 1991.
10. Lou Y, Klegerman M, Muhammad A, Dai X, and Groves M: Initial characterization of an antineoplastic, polysaccharide-rich extract of Mycobacterium bovis BCG, Tice® substrain. Anticancer Res 14: 1469-1476, 1994.
11. Klegerman M, Zeunert P, Lou Y, Devadoss P, and Groves M: Inhibition of murine sarcoma cell adherence to polystyrene substrate by Bacillus Calmette-Guérin: Evidence for fibronectin-mediated direct antitumor activity of BCG. Cancer Invest 11: 660-666, 1993.
12. Lou Y, Groves M, and Klegerman M: In-vivo and in-vitro targeting of a murine sarcoma by gelatin microparticles loaded with a glycan (PS1). J Pharm Pharmacol 46: 863-866, 1994.
13. Olson W, Groves M, and Klegerman M: Cell mass of Mycobacterium bovis BCG estimated by gas chromatography. Biologicals 18: 83-88, 1990.
14. Farrugia C, and Groves M: Effect of molecular weight profile on gelatin nanoparticulate formation. Pharm Sci 1: S-195, 1998.
15. Papilian-Todorutiu C, and Daicoviciu D: Response of B-16 melanoma and Lewis lung carcinoma to BCG immunoprophylaxis. Morphol-Embryol 33: 55-69, 1987.
16. Papilian-Todorutiu C, Risca R, Mulea R, and Daicoviciu D: The effect of BCG-activated macrophages on the B-16 melanoma. Morphol-Embryol 36: 129-134, 1990.
17. Donmez C, and Groves M: Activity of a mycobacterial antineoplastic glycan against human breast cancer. Anticancer Res 17: 445-450, 1997.
18. Friess W, Zhou W, and Groves M: In-vivo activity of collagen matrices containing PS1, an antineoplastic glycan, against murine sarcoma cells. Pharm Sci 2: 121-124, 1996.
19. Dekker S, Vink J, Vermeer B, Bruijn J, Mihm M, and Byers H: Differential effects of interleukin 1-α (IL-1α) or tumor necrosis factor-α (TNF-α) on motility of human melanoma cell lines on fibronectin. J Invest Dermatol 102: 898-905, 1994.
20. Abou-Zeid C, Ratliff T, Wiker H, Harboe M, Bennedsen J, and Rook G: Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG. Infect Immun 56: 3046-3051, 1988.
21. Ratliff T, McCarthy R, Telle W, and Brown E: Purification of a mycobacterial adhesin for fibronectin. Infect Immun 61: 1889-1894, 1993.
22. Schmitt F, Gross J, and Highberger J: States of aggregation of collagen. Symp Soc Exp Biol 9: 148-162, 1955.
23. Boedtker H, and Doty P: The native and denatured states of soluble collagen. J Am Chem Soc 78: 4267-4280, 1956.
24. Akiyama S, Olden K, and Yamada K: Fibronectin and integrins in invasion and metastasis. Cancer Metast Rev 14: 173-189, 1995
25. Longhurst C, and Jennings L: Integrin-mediated signal transduction. Cell Mol Life Sci 54: 514-526, 1998.